This pillar shows how public records can expose spending, unmet need, scientific movement, delivery capacity, policy experiments, regulated products, and the gaps between them. It asks which public signals can support a timely decision without claiming that incomplete data proves more than it does. Public data should guide investigation, not decorate a market-size claim.
Start with activity that can be checked
Healthcare is unusually visible because governments finance, regulate, study, purchase, and measure so much of it. Public data can show spending, utilization, grants, trials, product status, quality, provider capacity, workforce shortages, procurement, and payment experiments.
The first discipline is simple: record what the source actually shows before assigning meaning. Public data should guide investigation. It should not decorate a market-size claim.
Conditions, populations, spending, providers, outcomes, science, trials, products, rights, payment, pathways, and organizations connect around an opportunity hypothesis.
Build an opportunity graph
Connect the condition and patient population to utilization, spending, providers, outcomes, policy experiments, scientific funding, publications, trials, regulated products, rights, reimbursement, care pathways, and commercial activity. Keep identifiers, terminology, geography, dates, and dataset versions attached.
The graph is useful when it reveals a mismatch: money without outcomes, science without translation, products without adoption, patients without providers, reimbursement without workflow, capacity without useful technology, or rights without demand.
What the main public sources can show
Each source answers a different question. None should be treated as a complete market record.
| Source | Useful question | What it does not prove |
|---|---|---|
CMS |
What is paid for, used, and geographically concentrated? |
Value, causality, or unmet demand |
CMMI |
What payment and delivery changes are being tested? |
Future coverage or durable business |
NIH |
Where is scientific capital accumulating? |
Commercial demand or clinical success |
NLM and PubMed |
What is known, changing, or disputed? |
Translation or routine use |
ClinicalTrials.gov |
Where is science becoming intervention? |
Positive results or commercialization |
FDA and openFDA |
What products, precedents, and safety records exist? |
Adoption or economic value |
Provider files |
Who may be able to deliver care and where? |
Available capacity or willingness |
HRSA, CDC, AHRQ |
Where are burden, shortages, quality, and access gaps? |
A workable local service model |
USAspending and SAM.gov |
What is government buying or seeking? |
A procurement win |
Patent records |
Where are parties seeking future control? |
Ownership, enforceability, or demand |
Open Payments |
Where do disclosed relationships exist? |
Influence or endorsement |
State data |
Where do local payment, capacity, and need differ? |
National transferability |
Look at intersections
Individual signals are often weak. Combinations can justify a closer look. High spending, poor outcomes, and fragmented delivery may point to expensive failure. Sustained public research and strong publications with weak adoption may point to a translational gap. Regulated products with evidence but low use may point to workflow or market conditioning.
Other useful combinations include policy experiments with growing provider participation, disease burden with workforce shortage and available technology, or active trials with weak category understanding. These patterns generate hypotheses. They are not findings by themselves.
Observable public mismatches are separated from the hypotheses they may justify.
Score without hiding uncertainty
A public-signal score can cover spending, science, clinical translation, delivery, policy, rights, and commercial activity. Every dimension also needs confidence, evidence quality, freshness, contrary evidence, and the next test.
A high score built from stale or indirect sources is not equivalent to one supported by current utilization and external commitment. Do not average away a missing provider base, weak reimbursement, or an exhausted care pathway.
Use machines for the repeatable work
An AI Workforce™ can maintain source inventories, detect new releases and schema changes, normalize terminology and entities, map geography, find unusual change, connect related signals, prepare sourced summaries, and refresh opportunity records.
People decide whether the pattern matters, whether the explanation is plausible, and what action is warranted. Machine synthesis must remain traceable. An AI inference stays labeled as an inference until evidence supports something stronger.
An AI workforce discovers, normalizes, connects, scores, and maintains public signals before a person judges meaning and action.
Size the market from real activity
Begin with actual utilization and paid activity where possible. Then examine patient counts, provider counts, geography, reimbursement, the addressable workflow, and adoption constraints. Generic market reports can be useful context, but they should not replace the operating record.
The serviceable market is the portion of current or plausible activity that a defined delivery model can reach, influence, and support. National averages can hide local density, payer rules, state law, and provider capacity.
Keep the record honest
Every conclusion needs the source, dataset, date, period, coverage, calculation, assumptions, limitations, confidence, contradictions, and next validation step. Raw observations should remain separate from interpretation.
Evidence also expires. Coverage changes, trials report, products gain or lose status, providers merge, codes change, and workforce conditions move. A monitoring trigger should state what external change would reopen a decision.
Move from signal to decision
A signal is something observed. A pattern is a recurring relationship. A hypothesis is one possible explanation. An opportunity adds plausible value and an identifiable beneficiary. A validated opportunity has external commitment or real-world evidence. A commercial thesis adds a credible path to value capture.
The cheapest next step may be a clinician interview, cohort query, reimbursement review, provider map, data-access request, design-partner discussion, or licensing conversation. The result should lead to investigate, build, partner, license, wait, monitor, or stop.
An observation becomes a pattern, bounded hypothesis, tested opportunity, commercial thesis, and monitored human decision.